On July 26, 2022, China Securities Regulatory Commission approved MGI’s IPO registration on the sci-tech innovation board.

3M (NYSE: MMM) today announced its intent to spin off its Health Care business, resulting in two world-class public companies well positioned to pursue their respective growth plans.

DiaSorin said Friday it received 501(k) clearance from the US Food and Drug Administration to market its Liaison MeMed BV, a high-throughput immune-response assay that can differentiate between bacterial and viral infections.

Qiagen on Tuesday afternoon reported strong year-over-year sales growth in its core non-COVID-related product portfolio, prompting the company to raise its full-year revenue and earnings guidance even as its COVID-19-related business remains volatile.

On July 23, 2022, the China Enterprise Evaluation Association released the "2021 China Top 500 New Economy Enterprises" list. China's Top 500 New Economy Enterprises is hosted by the China Enterprise Evaluation Association

Ginkgo Bioworks said on Monday that it has entered into a definitive agreement to acquire Zymergen in an all-stock deal.

Chinese sequencing tech company GeneMind Biosciences said earlier this month that its single-molecule DNA sequencer, GenoCare 1600 (originally developed by Direct Genomics), has been approved by China's National Medical Products Administration (NMPA) for clinical and diagnostic applications.

Recently, the Wondfo Biotech COVID-19 Antigen Detection Kit (Immunochromatography Method) was included in the WHO (World Health Organization) list for emergency use by the WHO, which can be purchased by other countries and regions.

PamGene International BV said on Thursday that it has obtained CE-IVD registration for its IOpener-NSCLC blood test to help guide immunotherapy in advanced-stage cancer patients.

The US Food and Drug Administration this week granted Emergency Use Authorization for a molecular SARS-CoV-2 test from Predicine.

The semi-annual report shows that Maccura spent 166 million CNY to complete the acquisition of 100% equity of Beijing Dawei Biotechnology Co., Ltd. (hereinafter referred to as " Dawei ").

Danaher's diversification of its business conglomerate has led to increased stability and second quarter revenue growth in the face of headwinds, company executives said on Thursday

Roche on Thursday reported its Diagnostics division revenues grew 10 percent year over year in the first half of the year but said that it expects the momentum from COVID-19 testing-related sales to slow throughout the rest of the year.

Recently, Wondfo's 2019-nCoV Antigen Test (Lateral Flow Method) is listed by WHO (World Health Organization) for emergency use listing (EUL), available for purchase in other countries and regions in worldwide.

Danaher subsidiary Beckman Coulter and cell morphology firm Scopio Labs announced on Wednesday a deal to expand Scopio's digital blood smear platforms.